


=&gt; d que 126

L1

STR



VAR G1=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L3

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 1

GGCAT IS MCY LOQ UNS AT 2

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L4

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 1

GGCAT IS MCY LOQ UNS AT 2

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 4



STEREO ATTRIBUTES: NONE

L8



3870 SEA FILE=REGISTRY SSS FUL L1 AND (L3 OR L4)

L23

STR



Ak @21



VAR G1=CH3/6/26

VAR G5=H/21/23

VAR G8=H/21

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 1

GGCAT IS MCY LOQ UNS AT 2

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 15


STEREO ATTRIBUTES: NONE

L24

STR



Ak @21



VAR G1=CH3/6/26

VAR G5=H/21/23

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 1

GGCAT IS MCY LOQ UNS AT 2

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE




L26

582 SEA FILE=REGISTRY SUB=L8 SSS FUL L23 OR L24

=&gt; d bib abs hitstr 1-9

L28 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:814466 CAPLUS  
DN 133:362714  
TI Preparation of cyclic compounds having antagonism against .beta.-beta  
chemokine receptor (CCR5)  
IN Shiraishi, Mitsuru; Baba, Masanori; Seto, Masaki; Kanzaki, Naoyuki;  
Nishimura, Osamu  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 282 pp.  
CODEN: PIXXD2  
DT **Patent**  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----		-----	-----	-----
PI	WO 2000068203	A1	20001116	WO 2000-JP2825	20000428
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ,				
	DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC,				
	LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG,				
	SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG,				
	KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001026586	A2	20010130	JP 2000-134249	20000428
PRAI	JP 1999-127724		19990507		
OS	MARPAT 133:362714				
GI					



AB Comps. of general formula R1-X1-W-X2-Z1-Z2-R2 or salts thereof [wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or divalent group having 1-4 C atoms in the straight chain moiety; W is a divalent group represented by general formula Q, Q1, or Q2 (wherein A and B are each an optionally substituted five- to seven-membered ring; E1 and E4 are each optionally substituted carbon or N; E2 and E3 are each optionally substituted carbon or N, O, or

optionally

oxidized S; and a and b are each a single bond or a double bond); X2 is a divalent group constituting a C1-4 straight chain moiety; Z1 is a single bond or a divalent cyclic group; Z2 is a free valency or divalent group having 1-4 C atoms in the straight chain moiety; and R2 is (1) optionally substituted, quaternized, or oxidized amino, (2) optionally substituted N-contg. heterocyclyl optionally contg. S or O and optionally quaternized or oxidized at the N atom, (3) group bonding through S atom, etc.] are prepd. These comps. exhibit preventive and therapeutic effects against HIV infections or AIDS. Thus, chlorination of 7-[(2-propoxybenzyl)oxy]-1,1-dioxo-2,3-dihydro-1-benzothiepin-4-carboxylic acid by SOCl2 in the presence of one drop of DMF at room temp. for 1 h followed by

condensation

with 4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]aniline in the presence of Et3N in THF at room temp. for 2 days gave N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-7-[(2-propoxybenzyl)oxy]-1,1-dioxo-2,3-dihydro-1-benzothiepin-4-carboxamide (I). I in vitro inhibited the binding of 125I-RANTES to recombinant CCR5 receptor by 98%. A

capsule

and a tablet formulation contg. I were prepd.

IT **307301-89-9P**

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS)

RN 307301-89-9 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[trans-4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]cyclohexyl]-, (2E)- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT **307301-90-2P 307301-94-6P 307301-96-8P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS)

RN 307301-90-2 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[trans-4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]cyclohexyl]-, (2E)- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 307301-94-6 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-furanyl]-N-[trans-4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]cyclohexyl]-, (2E)- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.  
Double bond geometry as shown.



RN 307301-96-8 CAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[trans-4-[[ (2E)-3-[4-(4-methylphenyl)-2-furanyl]-1-oxo-2-propenyl]amino]cyclohexyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.



IT 229007-97-0 229008-01-9 307301-92-4


RL: RCT (Reactant)

(prepn. of cyclic compds. having antagonism against CCR 5 receptor for preventives and therapeutics for HIV and AIDS)

RN 229007-97-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-01-9 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 307301-92-4 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 14

RE

- (1) American Chemical Society; CAPLUS
- (3) Takeda Chemical Industries Ltd; JP 11263764 A CAPLUS
- (4) Takeda Chemical Industries Ltd; JP 2000128782 A CAPLUS
- (5) Takeda Chemical Industries Ltd; JP 2000128842 A CAPLUS
- (6) Takeda Chemical Industries Ltd; US 6096780 A CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT



L28 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 2000:191072 CAPLUS

DN 132:238690

TI Synthesis of 5,5'-diformyl-2,2'-difuran and its derivatives and apparatus therefor

IN Burger, Gregory James; Wills, Alan Douglas

PA S. Afr.

SO PCT Int. Appl., 13 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000015623	A1	20000323	WO 1999-ZA87	19990915
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9964346	A1	20000403	AU 1999-64346	19990915
	EP 1036071	A1	20000920	EP 1999-952044	19990915
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRAI ZA 1998-8414 19980915

WO 1999-ZA87 19990915

AB 5,5'-Diformyl-2,2'-difuran and derivs. thereof are synthesized by irradiating furfural or a deriv. thereof by itself or with a substance capable of reacting or condensing therewith. The prodn. of these potential monomers is achieved in good yield and purity and avoids the

use of high temps., metal powders, and tedious work-up procedures of prior-art

methods. Typically, 5,5'-diformyl-2,2'-difuran was prepd. in good yield by photochem. irradiating furfural or a mixt. of furfural and 5-bromo-2-furfural. In the latter case an acid scavenger is present.

The


process may be carried out continuously, the 5-bromo-2-furfural acting as a catalyst, the furfural being added, and the product being harvested continuously.

IT 261712-43-0P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(photochem. synthesis of 5,5'-diformyl-2,2'-difuran and derivs. thereof)

RN 261712-43-0 CAPLUS

CN 2-Propen-1-one, 3,3'-[2,2'-bifuran]-5,5'-diylbis[1-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 3

RE

- (1) Itahara, T; JOURNAL OF ORGANIC CHEMISTRY 1985, V50(25), P5272 CAPLUS
- (2) Maerkl, G; TETRAHEDRON 1996, V52(36), P11763 CAPLUS
- (3) Tymyanskii, Y; JOURNAL OF ORGANIC CHEMISTRY OF THE USSR, ENGLISH TRANSLATION 1988, V24(2), P407

L28 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1999:747238 CAPLUS

DN 132:7605

TI Laser information recording medium and novel oxonol compound

IN Saito, Naoki; Wariishi, Koji; Shibata, Michihiro

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 43 pp.

CODEN: JKXXAF

DT **Patent**

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11321110	A2	19991124	JP 1998-153877	19980519

OS MARPAT 132:7605

GI For diagram(s), see printed CA Issue.

AB The title recording medium contains an oxonol compd. I (R1, R2, R3= substituent; Xk+ = onium ion; r = 1-5; n = 0, 1; p, q = 0-4 (p+q .gtoreq. 1); when p or q is .gtoreq.2, 2 R1 or R2 may joint with benzene ring to form condensed ring; k = 1-10) in its recording layer, wherein the center of the methine group may be substituted with Me, Et, Ph, 4-pyridyl, methoxy, phenoxy. The invention recording material shows superior reading

property and stability of the recording property for a long time.

IT **250787-58-7**

RL: TEM (Technical or engineered material use); USES (Uses)  
(contained in recording layer for optical recording material)


RN 250787-58-7 CAPLUS

CN 4,4'-Bipyridinium, 1,1'-bis(2-methyl-1-propenyl)-, salt with  
2-[5-(3-hydroxy-1,1-dioxidobenzo[b]thien-2-yl)-3-phenyl-2,4-pentadienylidene]benzo[b]thiophen-3(2H)-one 1,1-dioxide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 250787-57-6


CMF C18 H22 N2



CM 2

CRN 250787-50-9

CMF C27 H17 O6 S2



L28 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1999:421672 CAPLUS

DN 131:73571

TI Preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compounds as MCP-1 receptor antagonists.

IN Shiraishi, Mitsuru; Kitayoshi, Takahito; Aramaki, Yoshio; Honda, Susumu; Oda, Tsuneo

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 513 pp.




CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932468	A1	19990701	WO 1998-JP5707	19981217
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 9813686	A	20001010	BR 1998-13686	19981212
	AU 9916830	A1	19990712	AU 1999-16830	19981217
	EP 1040103	A1	20001004	EP 1998-961383	19981217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	US 6166006	A	20001226	US 1998-213379	19981217
	JP 11263764	A2	19990928	JP 1998-360780	19981218
	NO 2000003133	A	20000809	NO 2000-3133	20000616
PRAI	JP 1997-351481		19971219		
	WO 1998-JP5707		19981217		
OS	MARPAT 131:73571				
GI					



AB Title compds. I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered arom. ring; X = S, O,

(substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring;  
 Z = bond, divalent group; R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group], were prepd. Thus, 7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2

and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide (II). II at 1 .mu.M

inhibited MCP-1 induced chemotaxis in CHO cells by 89%. A II capsule compn. is given.

IT 229005-41-8P 229005-42-9P 229005-43-0P  
 229005-44-1P 229005-45-2P 229005-46-3P  
 229006-01-3P 229006-02-4P 229006-06-8P  
 229006-08-0P 229006-11-5P 229006-12-6P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229005-41-8 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-42-9 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-43-0 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-44-1 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-45-2 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-46-3 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-01-3 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 229006-02-4 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-11-5 CAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[ (2E)-3-[5-(4-methylphenyl)-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● I<sup>-</sup>

RN 229006-12-6 CAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[ (2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 62806-32-0P 229007-96-9P 229007-97-0P  
 229007-99-2P 229008-00-8P 229008-01-9P  
 229008-54-2P 229008-55-3P 229008-56-4P  
 229008-57-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides,  
 naphthalenecarboxamides, and related compds. as MCP-1 receptor  
 antagonists)

RN 62806-32-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, (2E)- (9CI) (CA  
 INDEX NAME)


Double bond geometry as shown.



RN 229007-96-9 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)-  
 (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229007-97-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229007-99-2 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-00-8 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-01-9 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-54-2 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-55-3 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)-  
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2

RE

- (1) Teijin Ltd; JP 07025756 A 1995 CAPLUS
- (2) Teijin Ltd; JP 07025757 A 1995 CAPLUS

L28 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1999:421562 CAPLUS

DN 131:87834

TI Preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compounds as CCR5 antagonists.

IN Nishimura, Osamu; Baba, Masanori; Sawada, Hidekazu; Kanzaki, Naoyuki; Kuroshima, Ken-ichi; Shiraishi, Mitsuru; Aramaki, Yoshio

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 516 pp.




CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932100	A2	19990701	WO 1998-JP5708	19981217
	WO 9932100	A3	19990910		
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9916831	A1	19990712	AU 1999-16831	19981217
	EP 1039899	A2	20001004	EP 1998-961384	19981217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9813691	A	20001010	BR 1998-13691	19981217
	JP 2000128782	A2	20000509	JP 1998-360820	19981218
	US 6096780	A	20000801	US 1999-377040	19990819
	NO 2000003179	A	20000619	NO 2000-3179	20000619
PRAI	JP 1997-351480		19971219		
	JP 1998-218875		19980803		
	JP 1998-234388		19980820		
	JP 1998-234398		19980820		
	US 1998-104845		19981016		
	WO 1998-JP5708		19981217		
OS	MARPAT 131:87834				
GI					



AB A pharmaceutical compn. for antagonizing CCR5 comprises I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered arom. ring; X = S, O, (substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group;

R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group]. Thus, 7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-

(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide (II). A II capsule compn. is given.

IT 229005-41-8P 229005-42-9P 229005-43-0P  
229005-44-1P 229005-45-2P 229005-46-3P  
229006-01-3P 229006-02-4P 229006-06-8P  
229006-08-0P 229006-11-5P 229006-12-6P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229005-41-8 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 229005-42-9 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-43-0 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-44-1 CAPLUS

CN 2-Propenamide, 3-[5-(4-methylphenyl)-2-furanyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-45-2 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229005-46-3 CAPLUS

CN 2-Propenamide, 3-[4-(4-methylphenyl)-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-01-3 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 CAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-11-5 CAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[ (2E)-3-[5-(4-methylphenyl)-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● I<sup>-</sup>

RN 229006-12-6 CAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● I<sup>-</sup>


IT 62806-32-0P 229007-96-9P 229007-97-0P  
229007-99-2P 229008-00-8P 229008-01-9P  
229008-54-2P 229008-55-3P 229008-56-4P  
229008-57-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of benzoxepinecarboxamides, benzocycloheptenecarboxamides,  
naphthalenecarboxamides, and related compds. as MCP-1 receptor  
antagonists)

RN 62806-32-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229007-96-9 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229007-97-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-thienyl]-, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229007-99-2 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methylphenyl)-2-furanyl]-, methyl ester, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-00-8 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, methyl ester, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-01-9 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-methylphenyl)-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-54-2 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-55-3 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 CAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





L28 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1998:661889 CAPLUS

DN 129:343825

TI Organic thin films and their production method by photochemical reaction

IN Nakao, Yukiyasu; Fuchigami, Hiroyuki; Kurata, Hiroyuki; Kakuta, Makoto

PA Mitsubishi Electric Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10273529	A2	19981013	JP 1997-78290	19970328
AB	The films of oligomers and/or polymers deposited on substrates are obtained by photochem. reaction of same or different kinds of low-mol.-wt.				

arom. compds. The reaction processes involves heating the arom. compds. in vacuo to generate their mol. beams, then exposing the beams on substrates, simultaneously irradiating visible light or UV light to the mols. provided that .gtoreq.1 of the mols. can absorb the light. Thus, evapg. biphenyl dithiol and biphenyl diethynyl in vacuo and irradiating laser at wave length 248 nm to the mols. gave a transparent deposition film having smooth surface.

IT **215360-51-3P**, 4,4'-Diacetylbiphenyl-diethynylbithiophene copolymer,sru


RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
(vapor deposition of arom. org. films by photopolymn.)

RN 215360-51-3 CAPLUS

CN

Poly[[2,2'-bithiophene]-5,5'-diyl(3-oxo-1-propene-1,3-diyl)[1,1'-biphenyl]-4,4'-diyl(1-oxo-2-propene-1,3-diyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



QAZI

09/619584

PAGE 1-B

] n

L28 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1998:424230 CAPLUS

DN 129:81730

TI Preparation of (hetero)arylacrylates as modulators of proteins with phosphotyrosine recognition units.

IN Mjalli, Adnan; Sarshar, Sepehr; Cao, Xiaodong; Bakir, Farid

PA Ontogen Corp., USA

SO PCT Int. Appl., 202 pp.


CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827065	A1	19980625	WO 1996-US20508	19961216
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9715667	A1	19980715	AU 1997-15667	19961216
	EP 946518	A1	19991006	EP 1996-945409	19961216
	R: CH, DE, ES, FR, GB, IT, LI, SE				
PRAI	US 1995-543630		19951016		
	WO 1996-US20508		19961216		
OS	MARPAT 129:81730				
GI					



AB YXC(R'):C(R'')CO<sub>2</sub>R''' [R', R'' = H, halo, cyano, NO<sub>2</sub>, trihalomethyl, alkyl, arylalkyl; R''' = H, (substituted) alkyl, aryl, arylalkyl; X = aryl; Y = H, (substituted) CO<sub>2</sub>CHCO, COCO, COCHOH, imidazolyl, thiazolyl, oxazolyl, quinoxalinyl, pyridopyrazinyl, etc.], were prepd. Thus, title compd. (I) (general prepn. given) inhibited protein tyrosine phosphatase 1B with

IC50

= 0.072 .mu.M.

IT 207867-36-5P 207867-37-6P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (hetero)arylacrylates as modulators of proteins with phosphotyrosine recognition units)

RN 207867-36-5 CAPLUS

CN Hexanoic acid,

6-[[[2-[5-(2-carboxyethenyl)-2-thienyl]-4-(4-methoxyphenyl)-1-(2-phenylpropyl)-1H-imidazol-5-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 207867-37-6 CAPLUS


CN Hexanoic acid,

6-[[[2-[5-(2-carboxyethenyl)-2-thienyl]-4-(4-methoxyphenyl)-1-(2-phenylpropyl)-1H-imidazol-5-yl]carbonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 207867-36-5

CMF C33 H35 N3 O6 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2

QAZI

09/619584




L28 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:352632 CAPLUS  
 DN 129:27942  
 TI Imidazole derivatives useful as modulators of multi drug resistances  
 IN Mjalli, Adnan M. M.; Sarshar, Sepehr  
 PA Ontogen Corp., USA  
 SO U.S., 24 pp. Cont.-in-part of U.S. 5,700,826.  
 CODEN: USXXAM

DT **Patent**  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5756527	A	19980526	US 1997-845322	19970425
	US 5700826	A	19971223	US 1995-481118	19950607
	AU 9724827	A1	19981029	AU 1997-24827	19970611
	JP 11001476	A2	19990106	JP 1997-192989	19970613
PRAI	US 1995-481118		19950607		
	US 1997-845322		19970425		
OS	MARPAT 129:27942				
GI					



AB The title compds. [I; R1 = mono-, di-, and tri-substituted Ph or thienyl, etc.; R2, R3 = mono-, di-, and tri-substituted Ph wherein the substituents are independently selected from: (i) halo; (ii) C1-6 alkylamino, or di(C1-6 alkyl)amino; R4 = H] are prepd. I are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents. Thus, a mixt. of the proper dione, aldehyde and AcONH4 in AcOH was heated to 80-140.degree. to give 82% the title compd. (II), which was tested and showed 3H-vinblastine accumulation of 2.4 (.mu.M)<sup>2</sup> in the CEM/VLB1000 cell line.

IT 208036-56-0P 208036-57-1P 208036-60-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic


preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(imidazole derivs. useful as modulators of multi drug resistances)

RN 208036-56-0 CAPLUS

CN 2-Propenoic acid,

3-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-  
2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 208036-57-1 CAPLUS

CN 2-Propenoic acid,

3-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-  
3-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 208036-60-6 CAPLUS

CN 2-Propenoic acid,

3-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-yl]-  
2-thienyl]-, 1-methylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





L28 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1998:324830 CAPLUS

DN 129:27883

TI Preparation of thiophene derivatives as immunostimulants

IN Chang, Ching-te; Chen, Kuo-mou; Liu, Wann-huang; Lin, Fen-lan; Wu, Rong-tsun

PA Industrial Technology Research Institute, Taiwan

SO U.S., 29 pp. Cont.-in-part of U.S. Ser. No. 302,278.

CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753692	A	19980519	US 1995-468522	19950606
	US 5602170	A	19970211	US 1994-302278	19940908
PRAI	US 1992-838516		19920219		
	US 1994-302278		19940908		

OS MARPAT 129:27883


AB AZmB [I; A,B = H, halo, alk(en)yl, carboxy(alkyl), etc.; Z = 2,5-thiophenediyl; m = 1-4] were prepd. Thus, 2-iodothiophene was autocondensed to give 2,2'-bithiophene. Data for biol. activity of I were given.

IT **162691-96-5P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of thiophene derivs. as immunostimulants)

RN 162691-96-5 CAPLUS

CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



QAZI

09/619584


=> d bib abs hitstr 10-35

L28 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:324829 CAPLUS  
 DN 129:27943  
 TI Preparation of heterocyclic compounds as modulators of proteins with  
 phosphotyrosine recognition units  
 IN Mjalli, Adnan; Sarshar, Sepehr; Cao, Xiaodong; Bakir, Farid  
 PA Ontogen Corp., USA  
 SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 543,630.  
 CODEN: USXXAM

DT **Patent**  
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753687	A	19980519	US 1996-766114	19961216
	US 5770620	A	19980623	US 1995-543630	19951016
	US 5965558	A	19991012	US 1997-960637	19971029
	US 6150532	A	20001121	US 1998-210076	19981211
PRAI	US 1995-543630		19951016		
	US 1995-17610		19950619		
	US 1996-766114		19961216		
	US 1997-960637		19971029		
OS	MARPAT 129:27943				
GI					



AB The title compds. I [at least one of R1 - R4 is XC(R'):C(R'')CO2R'''; R', R'' = H, halo, etc.; R''' = H, alkyl, etc.; X = mono-, di-, or trisubstituted aryl; the remaining of R1, R2, R3, R4 are independently selected from H, alkyl, etc.] are prepd. The title compds. in vitro showed IC50 values of 0.072 .mu.M to 31 .mu.M against PTP1B.

IT **207867-37-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of heterocyclic compds. as modulators of proteins with  
 phosphotyrosine recognition units)

RN 207867-37-6 CAPLUS

CN Hexanoic acid,

6-[[[2-[5-(2-carboxyethenyl)-2-thienyl]-4-(4-methoxyphenyl)-  
 1-(2-phenylpropyl)-1H-imidazol-5-yl]carbonyl]amino]-,  
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 207867-36-5

QAZI

09/619584


CMF C33 H35 N3 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



L28 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:282404 CAPLUS  
 DN 128:321558  
 TI Preparation of thiophene compounds as antiinflammatory and antitumor agents  
 IN Chang, Ching-te; Chen, Kuo-mou; Liu, Wann-huang; Lin, Fen-lan; Wu, Rong-tsun  
 PA Industrial Technology Research Institute, Taiwan  
 SO U.S., 34 pp. Cont.-in-part of U.S. 5,602,170.  
 CODEN: USXXAM  
 DT **Patent**  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5747525	A	19980505	US 1995-468253	19950606
	US 5602170	A	19970211	US 1994-302278	19940908
PRAI	US 1992-838516		19920219		
	US 1994-302278		19940908		
OS	MARPAT 128:321558				
AB	AZmB [I; A,B = H, halo, alkyl, carboxy(alkyl), alkoxy, etc.; Z = 2,5-thiophenediyl; m = 1-4] were prepd. Thus, 2-iodothiophene was subjected to Ullman reaction and the product subjected to Vilsmier reaction to give HZ2CHO. Data for biol. activity of I were given.				
IT	<b>162691-96-5P</b> RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of thiophene compds. as antiinflammatory and antitumor agents)				
RN	162691-96-5 CAPLUS				
CN	2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)				



L28 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:81044 CAPLUS  
 DN 128:192655  
 TI Preparation of 4-phenylpyridine derivatives as endothelin antagonists  
 IN Sakurai, Kuniya; Niwa, Seiji; Oono, Seiji; Uchita, Hirohisa  
 PA Ajinomoto Co., Inc., Japan  
 SO Jpn. Kokai Tokkyo Koho, 95 pp.  
 CODEN: JKXXAF

DT **Patent**  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 10029979	A2	19980203	JP 1997-93782	19970411
PRAI	JP 1996-91272		19960412		
OS	MARPAT 128:192655				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. (I; R1 - R11 = H, halo, OH, NH2, NO2, lower alkyl, alkoxy, alkenyl, alkylamino, alkylthio, alkanoyl, hydroxyalkyl, hydroxyalkoxy, hydroxyalkenyl, haloalkyl, haloalkoxy, or haloalkenyl, aryl-lower alkoxy, aroyl; or two of R1 - R5 groups or two of R7 - R11 groups are linked to each other to form a ring; R6 = an acidic functional group; R12 = aryl, heteroaryl, heterocyclylcarbonyl, or groups listed for R1 - R5 and R7 - R11; X = CR13R14, NR15, O, S; Y = NR16, O, S, CR17:CR18; R13 - R18 = H, lower alkyl; Z = H, OH, CO2H, lower alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbamoyle, arylcarbamoyle, heteroarylcarbamoyle, NH2, alkylamino, arylamino, heteroarylamino, acylamino, O2CNR19R20, NR21CONR22R23, O-CO2R24, NR25CO2R26, OR27, O2CR28; R19 - R28 = H, lower alkyl, aryl, heteroaryl; or R19 and R20, R21 and

R22, R21 and R23, R22 and R23, or R25 and R26 are bonded to each other to form a ring; m = 0,1; n = 0-3) are prepd. They are useful for the treatment of

hypertension, Raynaud's disease, acute kidney failure, myocardial infarction, angina pectoris, cerebral infarction, atrophy of brain blood vessels, arteriosclerosis, bronchial asthma, stomach ulcer, acute liver failure, diabetes, endotoxin shock, multi-organ failure, disseminated intravascular agglutination, and/or cyclosporin-induced kidney disorders. Thus,

3-cyano-5-(3-hydroxy-1-propenyl)-4-(4-methoxyphenyl)-6-methyl-2-(3,4-methylenedioxyphenyl)pyridine was dissolved in toluene, treated with Bu3SnN3, and refluxed overnight to give 60.5% the title 4-phenyl-3-tetrazolylpyridine compd. (II). II in vitro inhibited the binding of [125I]endotoxin to a pig ventricular muscle membrane prepn. with a -pIC50 value of 8.1.

IT **203801-69-8P 203801-70-1P 203802-12-4P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(prepn. of phenylpyridine derivs. as endothelin antagonists for treatment endothelin-related diseases)

RN 203801-69-8 CAPLUS


CN Carbamic acid, 2-furanyl-, 3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl ester

(9CI) (CA INDEX NAME)




RN 203801-70-1 CAPLUS

CN 2-Furancarboxylic acid, 3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl ester (9CI) (CA INDEX NAME)



RN 203802-12-4 CAPLUS

CN 2-Propen-1-ol, 3-[6-(1,3-benzodioxol-5-yloxy)-2-(2-furanyl)-4-(4-methoxyphenyl)-5-(1H-tetrazol-5-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 203804-83-5P 203804-84-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of phenylpyridine derivs. as endothelin antagonists for  
treatment endothelin-related diseases)


RN 203804-83-5 CAPLUS

CN 2-Propenoic acid, 3-[6-(1,3-benzodioxol-5-yloxy)-5-cyano-2-(2-furanyl)-4-(4-methoxyphenyl)-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 203804-84-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-(1,3-benzodioxol-5-yloxy)-6-(2-furanyl)-5-(3-hydroxy-1-propenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





L28 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:684407 CAPLUS  
 DN 127:346232  
 TI Cephem derivatives containing substituted heterocyclylpyridiniomethyl  
 group antibacterials  
 IN Nishitani, Yasuhiro; Ishikura, Koji  
 PA Shionogi & Co. Ltd., Japan; Nishitani, Yasuhiro; Ishikura, Koji  
 SO PCT Int. Appl., 142 pp.  
 CODEN: PIXXD2  
 DT **Patent**  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9737996	A1	19971016	WO 1997-JP1161	19970404
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2250002	AA	19971016	CA 1997-2250002	19970404
	AU 9721784	A1	19971029	AU 1997-21784	19970404
	EP 893446	A1	19990127	EP 1997-914600	19970404
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, FI			
	CN 1215403	A	19990428	CN 1997-193623	19970404
PRAI	JP 1996-82531		19960404		
	WO 1997-JP1161		19970404		
OS	MARPAT 127:346232				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Cephem compds. such as I having groups of general formula II [Het = a mono- or poly-cyclic hetero-ring having one or more atoms selected from among N, O and S which may be the same or different from each other; R1 = H, optionally substituted lower alkyl or lower alkenyl; A = optionally substituted lower alkylene, lower alkenylene or a single bond while B = optionally substituted imino or a single bond, or alternatively A and B may be united to form a single bond; and D = a single bond or NH-CMe:NH] at the 3-position of the cephem ring, or salts or hydrates thereof, are prepd. Thus, III [R2 = CHO, R3 = H] in DMF was treated with (BOC)2O to give III [R2 = CHO, R3 = BOC], which was treated with MeO-NH2.H2O in MeOH to give III [R2 = CH:N-OMe, R3 = BOC], which was reduced with Zn and the resulting (aminomethyl)pyrrole deriv. treated with 1,1'-carbonyldiimidazole in THF to give III [R2 = 1-imidazolylcarbonylaminomethyl, R3 = BOC], which was reacted with cyanamide in DMF contg. NaH to give III [R2 = CH2-NH-CO-NH-CN, R3 = BOC]. This was

IT 197776-37-7P

RN 197776-37-7 CAPLUS


CC(=O)Nc1ccc(OC)cc1C(=O)N2C3C(C2)C(=C)C(C3)C(=C)C(C4=CC=CC=C4)C(=O)N5C(=C)C(C=C5)C(=O)N6C(=C)C(C=C6)C(=O)N7C(=C)C(C=C7)C(=O)N8C(=C)C(C=C8)C(=O)N9C(=C)C(C=C9)C(=O)N10C(=C)C(C=C10)C(=O)N11C(=C)C(C=C11)C(=O)N12C(=C)C(C=C12)C(=O)N13C(=C)C(C=C13)C(=O)N14C(=C)C(C=C14)C(=O)N15C(=C)C(C=C15)C(=O)N16C(=C)C(C=C16)C(=O)N17C(=C)C(C=C17)C(=O)N18C(=C)C(C=C18)C(=O)N19C(=C)C(C=C19)C(=O)N20C(=C)C(C=C20)C(=O)N21C(=C)C(C=C21)C(=O)N22C(=C)C(C=C22)C(=O)N23C(=C)C(C=C23)C(=O)N24C(=C)C(C=C24)C(=O)N25C(=C)C(C=C25)C(=O)N26C(=C)C(C=C26)C(=O)N27C(=C)C(C=C27)C(=O)N28C(=C)C(C=C28)C(=O)N29C(=C)C(C=C29)C(=O)N30C(=C)C(C=C30)C(=O)N31C(=C)C(C=C31)C(=O)N32C(=C)C(C=C32)C(=O)N33C(=C)C(C=C33)C(=O)N34C(=C)C(C=C34)C(=O)N35C(=C)C(C=C35)C(=O)N36C(=C)C(C=C36)C(=O)N37C(=C)C(C=C37)C(=O)N38C(=C)C(C=C38)C(=O)N39C(=C)C(C=C39)C(=O)N40C(=C)C(C=C40)C(=O)N41C(=C)C(C=C41)C(=O)N42C(=C)C(C=C42)C(=O)N43C(=C)C(C=C43)C(=O)N44C(=C)C(C=C44)C(=O)N45C(=C)C(C=C45)C(=O)N46C(=C)C(C=C46)C(=O)N47C(=C)C(C=C47)C(=O)N48C(=C)C(C=C48)C(=O)N49C(=C)C(C=C49)C(=O)N50C(=C)C(C=C50)C(=O)N51C(=C)C(C=C51)C(=O)N52C(=C)C(C=C52)C(=O)N53C(=C)C(C=C53)C(=O)N54C(=C)C(C=C54)C(=O)N55C(=C)C(C=C55)C(=O)N56C(=C)C(C=C56)C(=O)N57C(=C)C(C=C57)C(=O)N58C(=C)C(C=C58)C(=O)N59C(=C)C(C=C59)C(=O)N60C(=C)C(C=C60)C(=O)N61C(=C)C(C=C61)C(=O)N62C(=C)C(C=C62)C(=O)N63C(=C)C(C=C63)C(=O)N64C(=C)C(C=C64)C(=O)N65C(=C)C(C=C65)C(=O)N66C(=C)C(C=C66)C(=O)N67C(=C)C(C=C67)C(=O)N68C(=C)C(C=C68)C(=O)N69C(=C)C(C=C69)C(=O)N70C(=C)C(C=C70)C(=O)N71C(=C)C(C=C71)C(=O)N72C(=C)C(C=C72)C(=O)N73C(=C)C(C=C73)C(=O)N74C(=C)C(C=C74)C(=O)N75C(=C)C(C=C75)C(=O)N76C(=C)C(C=C76)C(=O)N77C(=C)C(C=C77)C(=O)N78C(=C)C(C=C78)C(=O)N79C(=C)C(C=C79)C(=O)N80C(=C)C(C=C80)C(=O)N81C(=C)C(C=C81)C(=O)N82C(=C)C(C=C82)C(=O)N83C(=C)C(C=C83)C(=O)N84C(=C)C(C=C84)C(=O)N85C(=C)C(C=C85)C(=O)N86C(=C)C(C=C86)C(=O)N87C(=C)C(C=C87)C(=O)N88C(=C)C(C=C88)C(=O)N89C(=C)C(C=C89)C(=O)N90C(=C)C(C=C90)C(=O)N91C(=C)C(C=C91)C(=O)N92C(=C)C(C=C92)C(=O)N93C(=C)C(C=C93)C(=O)N94C(=C)C(C=C94)C(=O)N95C(=C)C(C=C95)C(=O)N96C(=C)C(C=C96)C(=O)N97C(=C)C(C=C97)C(=O)N98C(=C)C(C=C98)C(=O)N99C(=C)C(C=C99)C(=O)N100C(=C)C(C=C100)C(=O)N101C(=C)C(C=C101)C(=O)N102C(=C)C(C=C102)C(=O)N103C(=C)C(C=C103)C(=O)N104C(=C)C(C=C104)C(=O)N105C(=C)C(C=C105)C(=O)N106C(=C)C(C=C106)C(=O)N107C(=C)C(C=C107)C(=O)N108C(=C)C(C=C108)C(=O)N109C(=C)C(C=C109)C(=O)N110C(=C)C(C=C110)C(=O)N111C(=C)C(C=C111)C(=O)N112C(=C)C(C=C112)C(=O)N113C(=C)C(C=C113)C(=O)N114C(=C)C(C=C114)C(=O)N115C(=C)C(C=C115)C(=O)N116C(=C)C(C=C116)C(=O)N117C(=C)C(C=C117)C(=O)N118C(=C)C(C=C118)C(=O)N119C(=C)C(C=C119)C(=O)N120C(=C)C(C=C120)C(=O)N121C(=C)C(C=C121)C(=O)N122C(=C)C(C=C122)C(=O)N123C(=C)C(C=C123)C(=O)N124C(=C)C(C=C124)C(=O)N125C(=C)C(C=C125)C(=O)N126C(=C)C(C=C126)C(=O)N127C(=C)C(C=C127)C(=O)N128C(=C)C(C=C128)C(=O)N129C(=C)C(C=C129)C(=O)N130C(=C)C(C=C130)C(=O)N131C(=C)C(C=C131)C(=O)N132C(=C)C(C=C132)C(=O)N133C(=C)C(C=C133)C(=O)N134C(=C)C(C=C134)C(=O)N135C(=C)C(C=C135)C(=O)N136C(=C)C(C=C136)C(=O)N137C(=C)C(C=C137)C(=O)N138C(=C)C(C=C138)C(=O)N139C(=C)C(C=C139)C(=O)N140C(=C)C(C=C140)C(=O)N141C(=C)C(C=C141)C(=O)N142C(=C)C(C=C142)C(=O)N143C(=C)C(C=C143)C(=O)N144C(=C)C(C=C144)C(=O)N145C(=C)C(C=C145)C(=O)N146C(=C)C(C=C146)C(=O)N147C(=C)C(C=C147)C(=O)N148C(=C)C(C=C148)C(=O)N149C(=C)C(C=C149)C(=O)N150C(=C)C(C=C150)C(=O)N151C(=C)C(C=C151)C(=O)N152C(=C)C(C=C152)C(=O)N153C(=C)C(C=C153)C(=O)N154C(=C)C(C=C154)C(=O)N155C(=C)C(C=C155)C(=O)N156C(=C)C(C=C156)C(=O)N157C(=C)C(C=C157)C(=O)N158C(=C)C(C=C158)C(=O)N159C(=C)C(C=C159)C(=O)N160C(=C)C(C=C160)C(=O)N161C(=C)C(C=C161)C(=O)N162C(=C)C(C=C162)C(=O)N163C(=C)C(C=C163)C(=O)N164C(=C)C(C=C164)C(=O)N165C(=C)C(C=C165)C(=O)N166C(=C)C(C=C166)C(=O)N167C(=C)C(C=C167)C(=O)N168C(=C)C(C=C168)C(=O)N169C(=C)C(C=C169)C(=O)N170C(=C)C(C=C170)C(=O)N171C(=C)C(C=C171)C(=O)N172C(=C)C(C=C172)C(=O)N173C(=C)C(C=C173)C(=O)N174C(=C)C(C=C174)C(=O)N175C(=C)C(C=C175)C(=O)N176C(=C)C(C=C176)C(=O)N177C(=C)C(C=C177)C(=O)N178C(=C)C(C=C178)C(=O)N179C(=C)C(C=C179)C(=O)N180C(=C)C(C=C180)C(=O)N181C(=C)C(C=C181)C(=O)N182C(=C)C(C=C182)C(=O)N183C(=C)C(C=C183)C(=O)N184C(=C)C(C=C184)C(=O)N185C(=C)C(C=C185)C(=O)N186C(=C)C(C=C186)C(=O)N187C(=C)C(C=C187)C(=O)N188C(=C)C(C=C188)C(=O)N189C(=C)C(C=C189)C(=O)N190C(=C)C(C=C190)C(=O)N191C(=C)C(C=C191)C(=O)N192C(=C)C(C=C192)C(=O)N193C(=C)C(C=C193)C(=O)N194C(=C)C(C=C194)C(=O)N195C(=C)C(C=C195)C(=O)N196C(=C)C(C=C196)C(=O)N197C(=C)C(C=C197)C(=O)N198C(=C)C(C=C198)C(=O)N199C(=C)C(C=C199)C(=O)N200C(=C)C(C=C200)C(=O)N201C(=C)C(C=C201)C(=O)N202C(=C)C(C=C202)C(=O)N203C(=C)C(C=C203)C(=O)N204C(=C)C(C=C204)C(=O)N205C(=C)C(C=C205)C(=O)N206C(=C)C(C=C206)

Absolute stereochemistry.  
Double bond geometry as shown.



L28 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:623162 CAPLUS  
 DN 127:293119  
 TI Preparation of bicyclic aromatic compounds  
 IN Bernardon, Jean-Michel  
 PA Centre International De Recherches Dermatologiques Galderma (C.I.R.D.  
 Galder, Fr.; Bernardon, Jean-Michel  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT **Patent**  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9733881	A1	19970918	WO 1997-FR391	19970305
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2746101	A1	19970919	FR 1996-3235	19960314
	FR 2746101	B1	19980430		
	CA 2218766	AA	19970918	CA 1997-2218766	19970305
	AU 9720305	A1	19971001	AU 1997-20305	19970305
	AU 704753	B2	19990506		
	EP 832081	A1	19980401	EP 1997-908308	19970305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1190394	A	19980812	CN 1997-190489	19970305
	JP 10509987	T2	19980929	JP 1997-532318	19970305
	JP 2991502	B2	19991220		
	BR 9702200	A	19990720	BR 1997-2200	19970305
	NO 9705192	A	19980114	NO 1997-5192	19971112
	US 6147255	A	20001114	US 1998-952804	19980126
PRAI	FR 1996-3235		19960314		
	WO 1997-FR391		19970305		
OS	MARPAT 127:293119				
GI					



I

AB Novel bicyclic arom. compds. I [R1 = Me, CH2OR5, COR6; Ar = = (un)substituted Ph, pyridyl, furyl, thienyl, pyrrolyl; X = CR8:CR9, C.tplbond.C; R2, R3 = H, alkyl, OR5, SR5; R2R3 = arom. ring; R5 = H,

alkyl, acyl; R6 = H, alkyl, NR'R''; R8, R9 = H, alkyl] and their use in pharmaceutical compns. useful in treatment of dermatol. conditions (no data) or their use in cosmetic compns. (no data) are disclosed. E.g., reaction of 3-tert-butyl-4-methoxyphenylboronic acid and 4-bromo-2-thiophenecarboxaldehyde gave

4-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde. The last was treated with tri-Et phosphonoacetate to give Et 4-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylate. The ester was converted to the corresponding acid.

IT 196960-59-5P 196960-61-9P 196960-62-0P

196960-63-1P 196960-64-2P 196960-65-3P

RL: BAC (Biological activity or effector, except adverse); BUU

(Biological

use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of bicyclic arom. compds.)

RN 196960-59-5 CAPLUS

CN 2-Propenoic acid,


3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
(9CI) (CA INDEX NAME)



RN 196960-61-9 CAPLUS

CN 2-Propenoic acid,


3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
(9CI) (CA INDEX NAME)



RN 196960-62-0 CAPLUS


CN 2-Propenoic acid,

3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
(9CI) (CA INDEX NAME)




RN 196960-63-1 CAPLUS

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 196960-64-2 CAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 CAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



IT 196961-00-9P 196961-02-1P 196961-04-3P


196961-06-5P 196961-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of bicyclic arom. compds.)

RN 196961-00-9 CAPLUS

CN 2-Propenoic acid,


3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-02-1 CAPLUS


CN 2-Propenoic acid,

3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-04-3 CAPLUS

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-06-5 CAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-08-7 CAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




L28 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:128100 CAPLUS  
 DN 126:225209  
 TI Preparation of thiophene derivatives as drugs  
 IN Chang, Ching-te; Chen, Kuo-mou; Liu, Wann-huang; Lin, Fen-lan; Wu, Rong-tsun  
 PA Industrial Technology Research Institute, Taiwan  
 SO U.S., 30 pp. Cont.-in-part of U.S. Ser. No. 838,516, abandoned.  
 CODEN: USXXAM

DT **Patent**  
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5602170	A	19970211	US 1994-302278	19940908
	US 5747525	A	19980505	US 1995-468253	19950606
	US 5753692	A	19980519	US 1995-468522	19950606
PRAI	US 1992-838516		19920219		
	US 1994-302278		19940908		
OS	MARPAT 126:225209				
AB	AZmB [I; A,B = H, alkyl, alken(o)yl, alkynyl, alkoxy, etc.; Z = thiophene-2,5-diyl; m = 1-4] were prepd. as antiinflammatory, antitumor, and antiviral agents, immunomodulators, etc. Thus, 2-iodothiophene was coupled over Cu and the formylated product converted in 2 steps to 5-ethynyl-2,2'-bithiophene. Data for biol. activity of I were given.				
IT	<b>162691-96-5P</b>				
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of thiophene derivs. as drugs)				
RN	162691-96-5 CAPLUS				
CN	2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)				





L28 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1997:127476 CAPLUS

DN 126:126920

TI Inhibition of phospholipase A2 for treatment of neurodegenerative disease,

method for identification of inhibitors of neuronal degeneration, and benzenesulfonamide phospholipase A2 inhibitor preparation

IN Rydel, Russel E.; Dappen, Michael S.; John, Varghese; Fang, Lawrence Yung-Sun; Thorsett, Eugene D.

PA Athena Neurosciences, Inc., USA; Rydel, Russel E.; Dappen, Michael S.; John, Varghese; Fang, Lawrence Yung-Sun; Thorsett, Eugene D.

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2


DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640982	A1	19961219	WO 1996-US9772	19960607
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI			
	US 5707821	A	19980113	US 1995-476464	19950607
	US 5866318	A	19990202	US 1995-476463	19950607
	AU 9663814	A1	19961230	AU 1996-63814	19960607
PRAI	US 1995-476463		19950607		
	US 1995-476464		19950607		
	US 1995-486392		19950607		
	WO 1996-US9772		19960607		

GI



AB Methods and compns. are provided for treating neurodegeneration in mammalian cells by administering a phospholipase A2 inhibitor. Also disclosed are methods for identifying agents which inhibit neuronal degeneration. Prepn. and activity of benzenesulfonamide phospholipase A2 inhibitors, e.g. AN36653 (I), is included.

IT **186457-39-6P**, AN 36724

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(phospholipase A2 inhibition for treatment of neurodegenerative disease, method for identification of inhibitors of neuronal degeneration, and benzenesulfonamide phospholipase A2 inhibitor prepn.)

RN 186457-39-6 CAPLUS

CN 2-Propenamide,

3-[2,2'-bithiophen]-5-yl-N-[4-[(cycloheptylamino)sulfonyl]phenyl]-N-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L28 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:85609 CAPLUS  
 DN 126:199793  
 TI Preparation of pyrazoloquinoline nucleosides as antitumors  
 IN Wolin, Ronald L.; Afonso, Adriano; Kelly, Joseph M.; Njoroge, F. George  
 PA Wolin; Ronald L., USA; Afonso; Adriano; Kelly; Joseph M.; Njoroge; F. George  
 SO U.S., 24 pp.  
 CODEN: USXXAM

DT **Patent**  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5595998	A	19970121	US 1994-357624	19941215
OS	MARPAT 126:199793				
GI					




AB Pyrazoloquinoline nucleosides I and II (R1 = CH2OH, alkyloxymethyl, CH2NH2, BnCO2CH2, BnOCH2, BzCH:CH; R2, R3 = OH, alkyl, COO, BnCOO, BnO; X = Cl, OH, H) as antitumors. Thus, I (R1-R3 = OBz; X = Cl) was prepd. and tested for its antitumor activity (ras p21 nucleotide exchange assay 17%; IC50 = 50 .mu.M).

IT **175543-50-7P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of pyrazoloquinoline nucleosides as antitumors)



RN 175543-50-7 CAPLUS

CN 2-Propen-1-one, 3-[5-(4-chloro-6-methoxy-3-methyl-1H-pyrazolo[3,4-b]quinolin-1-yl)-2-furanyl]-1-phenyl- (9CI) (CA INDEX NAME)



L28 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:580361 CAPLUS  
 DN 125:221564  
 TI Preparation of diphenylthiophene antiinflammatories  
 IN Wierzbicki, Michel; Sauveur, Frederic; Bonnet, Jacqueline; Tordjman, Charles  
 PA Adir Et Compagnie, Fr.  
 SO Eur. Pat. Appl., 21 pp.  
 CODEN: EPXXDW  
 DT **Patent**  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 728755	A1	19960828	EP 1996-400359	19960222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2730996	A1	19960830	FR 1995-2061	19950223
	FR 2730996	B1	19970620		
	CN 1142496	A	19970212	CN 1996-106004	19960217
	CN 1058965	B	20001129		
	FI 9600795	A	19960824	FI 1996-795	19960221
	AU 9645675	A1	19960829	AU 1996-45675	19960221
	AU 697832	B2	19981015		
	CA 2170097	AA	19960824	CA 1996-2170097	19960222
	NO 9600706	A	19960826	NO 1996-706	19960222
	JP 08253470	A2	19961001	JP 1996-35131	19960222
	US 5705525	A	19980106	US 1996-605537	19960222
	ZA 9601472	A	19960828	ZA 1996-1472	19960223
PRAI	FR 1995-2061		19950223		
OS	MARPAT 125:221564				
GI					



AB The title compds. [I; A = (un)substituted C1-5 alkylene; R1 = branched alkyl, H; R2 = H, alkyl, cyclohexyl, PhCH2; X1, X2, Y1, Y2 = H, halogen, alkoxy, alkyl, CF3], useful as antiinflammatories, are prepd. Thus, thiophene deriv. II, m.p. 96.degree., prepd. from the corresponding Et ester, demonstrated a IC50 for cyclooxygenase (PGE2) of 0.05 .mu.M and 0.03 .mu.M for lipoxxygenase (LTB4).


IT **181309-29-5P 181309-30-8P 181309-31-9P**  
**181309-32-0P 181309-33-1P 181309-34-2P**  
**181309-35-3P 181309-36-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of diphenylthiophene antiinflammatories)

RN 181309-29-5 CAPLUS

CN 2-Propenoic acid, 3-[4,5-bis(4-methoxyphenyl)-2-thienyl]-, ethyl ester,  
 (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181309-30-8 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-fluorophenyl)-5-(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181309-31-9 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methoxyphenyl)-4-(4-methylphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181309-32-0 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-methoxyphenyl)-4-[4-(trifluoromethyl)phenyl]-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181309-33-1 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181309-34-2 CAPLUS

CN 2-Butenoic acid, 3-[4,5-bis(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 181309-35-3 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-thienyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)



ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 181309-36-4 CAPLUS


CN 2-Propenoic acid, 3-[4,5-bis(4-methylphenyl)-2-thienyl]-, ethyl ester,  
(E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:497113 CAPLUS  
 DN 125:142773  
 TI Novel benzyl pyrimidines with antibacterial activity.  
 IN Guerry, Philippe; Jolidon, Synese; Masciadri, Raffaello; Stalder, Henri;  
 Then, Rudolf  
 PA F. Hoffmann-La Roche Ag, Switz.  
 SO PCT Int. Appl., 136 pp.  
 CODEN: PIXXD2  
 DT **Patent**  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9616046	A2	19960530	WO 1995-EP4451	19951113
	W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9641161	A1	19960617	AU 1996-41161	19951113
	AU 704911	B2	19990506		
	EP 793656	A1	19970910	EP 1995-939267	19951113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	CN 1166831	A	19971203	CN 1995-196398	19951113
	HU 77372	A2	19980330	HU 1997-1973	19951113
	BR 9509768	A	19980707	BR 1995-9768	19951113
	JP 11507009	T2	19990622	JP 1995-516521	19951113
	US 5763450	A	19980609	US 1997-836857	19970521
	FI 9702194	A	19970522	FI 1997-2194	19970522
	NO 9702393	A	19970529	NO 1997-2393	19970526
PRAI	CH 1994-3536		19941124		
	CH 1995-2704		19950925		
	WO 1995-EP4451		19951113		
OS	MARPAT 125:142773				
GI					



AB Substituted 5-benzyl-2,4-diaminopyrimidines of formula I [R1 = alkoxy; R2 = Br or alkoxy; R3 = aryl, heteroaryl, QR4; Q = CH<sub>2</sub>CH<sub>2</sub>, CH:CH, C.tplbond.C; R4 = aryl, heteroaryl, alkoxy carbonyl, or carbamoyl], and their readily hydrolyzable esters and pharmaceutically acceptable salts, can be used in the control or prevention of infectious diseases. Preps. of approx. 250 example compds. and many intermediates are described, plus bioassay results for selected compds. against 3 organisms. For example, quinoline deriv. II [R7 = CHO] was condensed with PhNHCH<sub>2</sub>CH<sub>2</sub>CN in DMSO in the presence of KOBu-tert to give 98% II [R7 = PhNHCH:C(CN)CH<sub>2</sub>]. This

was

then cyclocondensed with guanidine-HCl in EtOH in the presence of KOBu-tert to give 44% title compd. III, which was isolated as the trifluoroacetate (IV). IV inhibited purified dihydrofolate reductase (DHFR) of *Staphylococcus aureus* ATCC 25923 and *S. aureus* 157/4696 with IC<sub>50</sub> values of 0.0009 and 0.0500 .mu.M, resp., vs. 0.0340 .mu.M for trimethoprim. IV also had IC<sub>50</sub> of 0.0190 .mu.M against DHFR of *Pneumocystis carinii*, vs. 43.0 .mu.M for trimethoprim.


IT **179940-19-3P**

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of novel benzylpyrimidines as antibacterials)

RN 179940-19-3 CAPLUS

CN 2-Propenoic acid, 3-[5-[5-[(2,4-diamino-5-pyrimidinyl)methyl]-2,3-dimethoxyphenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)




IT **179940-41-1P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of novel benzylpyrimidines as antibacterials)

RN 179940-41-1 CAPLUS

CN 2-Propenoic acid, 3-[5-[5-[(2,4-diamino-5-pyrimidinyl)methyl]-2,3-dimethoxyphenyl]-2-furanyl]- (9CI) (CA INDEX NAME)



L28 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1995:520423 CAPLUS

DN 122:274041

TI thiophene compounds as antiviral, antiinflammatory, and immunoregulatory agents

IN Cho, Kintoku; Ryu, Manko; Chin, Kokubo; Hayashi, Funran; Go, Eisan

PA Ind Tech Res Inst, Japan

SO Jpn. Kokai Tokkyo Koho, 59 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07002665	A2	19950106	JP 1991-218295	19910829
OS	MARPAT 122:274041				
AB	Thiophene compds. or their pharmaceutically acceptable salts are useful				
as					

antiviral, antiinflammatory, and immunostimulant agents. These compds. can be isolated from plants such as Echinops grijsii or synthesized. As an example, bithiophene was prepd. by refluxing 2-iodothiophene in DMF at 153.degree. for 15 h. Biothiophene showed antiinflammatory activity in exptl. mice as detd. by the foot paw edema method.


IT 162691-96-5P 162691-97-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(plant or synthetic thiophene compds. as antiviral, antiinflammatory, and immunoregulatory agents)


RN 162691-96-5 CAPLUS

CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 162691-97-6 CAPLUS

CN 2-Propen-1-one, 3-[2,2'-bithiophen]-5-yl-1-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)






QAZI


09/619584

L28 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1994:41968 CAPLUS  
 DN 120:41968  
 TI Electrophotographic photoreceptor using stilbene or hydrazone compound as charge-transporting agent  
 IN Amano, Masayo; Kuroda, Masami; Kosho, Noboru  
 PA Fuji Electric Co Ltd, Japan  
 SO Jpn. Kokai Tokkyo Koho, 14 pp.  
 CODEN: JKXXAF  
 DT **Patent**  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05204175	A2	19930813	JP 1992-14380	19920130
GI					




AB The photoreceptor comprises a substrate coated with a photosensitive layer  
 contg. a stilbene compd. I or a hydrazone compd. II or III [R1-4, R7-10, R13-16 = (substituted) alkyl, aryl, heterocycle; R5-6, R11-12, R17-18 =  
 H, alkyl, aryl; n = 1-3] as a charge-transporting agent. The photoreceptor shows high sensitivity and durability in repeated use.  
 IT **151703-30-9 151703-34-3 151703-46-7**  
 RL: USES (Uses)  
 (charge-transporting agent, for electrophotog. photoreceptor)  
 RN 151703-30-9 CAPLUS  
 CN 2,2'-Bifuran, 5-(2,2-diphenylethenyl)-5'-(2-methyl-1-propenyl)- (9CI)  
 (CA INDEX NAME)




RN 151703-34-3 CAPLUS

CN 2,2':5',2''-Terfuran, 5-[2,2-bis(4-methylphenyl)ethenyl]-5''-(2-methyl-1-propenyl)- (9CI) (CA INDEX NAME)



RN 151703-46-7 CAPLUS




CN [2,2':5',2''-Terfuran]-5-carboxaldehyde, 5''-(2-methyl-1-propenyl)-, bis(4-methylphenyl)hydrazone (9CI) (CA INDEX NAME)





L28 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1992:173999 CAPLUS  
 DN 116:173999  
 TI Preparation of (carboxy dihydroxyheptenyl)sulfonylpyrroles as HMG-CoA reductase inhibitors  
 IN Hirai, Kentaro; Ishiba, Teruyuki; Koike, Haruo; Watanabe, Nasamichi  
 PA Shionogi and Co., Ltd., Japan  
 SO Eur. Pat. Appl., 29 pp.  
 CODEN: EPXXDW  
 DT **Patent**  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 464845	A1	19920108	EP 1991-111221	19910705
	EP 464845	B1	19960605		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5128366	A	19920707	US 1991-707805	19910530
	JP 04352767	A2	19921207	JP 1991-157518	19910531
	JP 3068665	B2	20000724		
	CA 2046146	AA	19920106	CA 1991-2046146	19910703
	CA 2046146	C	19970225		
	AT 138909	E	19960615	AT 1991-111221	19910705
	ES 2090177	T3	19961016	ES 1991-111221	19910705
PRAI	JP 1990-178564		19900705		
OS	MARPAT 116:173999				
GI					



AB Title compds. I [R1-R3 = H, (substituted) C1-6 alkyl, (substituted) aryl;  
 R4 = (substituted) C1-6 alkyl, -aralkyl, -aryl, -heteroaryl; X = vinylene,

ethylene; Y = CH(OH)CH<sub>2</sub>CH(OH)CH<sub>2</sub>CO<sub>2</sub>R<sub>5</sub>, Q; R<sub>5</sub> = H, C1-6 alkyl, aryl, aralkyl, pharmaceutically acceptable cation] were prepd. as HMG-CoA reductase inhibitors. Thus, 3-[4-(4-fluorophenyl)-2-isopropyl-1-(2-thienylsulfonyl)pyrrol-3-yl]-(E)-propenal (prepd. in 7 steps from Et isobutyrylacetate and 2-amino-4'-fluoroacetophenone) was condensed with AcCH<sub>2</sub>CO<sub>2</sub>Et and the product formed was subjected to borohydride redn. and hydrolysis of the resultant ester to give title compd. (E)-II. A no. of

I

had activities 1-4 times greater than Na mevinolin in in vitro HMG-CoA reductase inhibition tests.

IT

**139993-88-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. of, as intermediate for HMG-CoA reductase inhibitors)

RN 139993-88-7 CAPLUS

CN 1H-Pyrrole,

4-(4-fluorophenyl)-2-(1-methylethyl)-3-(3-oxo-1-propenyl)-1-(2-thienylsulfonyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L28 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1991:570596 CAPLUS  
 DN 115:170596  
 TI Thienylvinylfuran nonlinear optical material  
 IN Suzuki, Yasushi; Sugiyama, Yoshio; Mitamura, Shuichi  
 PA Nippon Steel Corp., Japan; Nippon Steel Chemical Co., Ltd.  
 SO Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF

DT **Patent**  
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 03122624	A2	19910524	JP 1989-259941	19891006
OS	MARPAT 115:170596				
GI					



AB A nonlinear optical furan deriv. I (R1 = alkyl; .gtoreq.1 of R2-3 = electron-attractive group, other is H) is claimed. The material is useful


for laser wave length conversion, optical modulation, optical communication, etc.,. A room temp.-stable crystal I (R1 = Me, R2 = H, R3 = p-CCF3C6H4) was laser-irradiated to show strong 2nd harmonics.

IT **136428-36-9 136428-37-0 136428-38-1**

RL: TEM (Technical or engineered material use); USES (Uses)  
 (nonlinear optical material, with thermal stability)


RN 136428-36-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[5-[3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 136428-37-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[5-[3-(4-chlorophenyl)-3-oxo-1-propenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 136428-38-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[5-[3-(1,3-benzodioxol-5-yl)-3-oxo-1-propenyl]-2-furanyl]-, methyl ester (9CI) (CA INDEX NAME)



L28 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1989:573977 CAPLUS  
 DN 111:173977  
 TI Preparation and formulation of 7-(butyl- or thienyl)-3,5-dihydroxy-6-heptenoate mevalonate analogs as anticholesteremics  
 IN Damon, Robert E., II; Wareing, James R.  
 PA Sandoz Pharmaceuticals Corp., USA  
 SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 816,664, abandoned.  
 CODEN: USXXAM  
 DT **Patent**  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4829081	A	19890509	US 1986-945428	19861222
	AU 8665994	A1	19870519	AU 1986-65994	19861021
	AU 598775	B2	19900705		
	JP 63501153	T2	19880428	JP 1986-505883	19861021
	HU 48208	A2	19890529	HU 1986-5313	19861021
	FI 8702299	A	19870525	FI 1987-2299	19870525
	DK 8703218	A	19870624	DK 1987-3218	19870624
	US 4927851	A	19900522	US 1988-242667	19880912
PRAI	US 1986-816664	19860107			
	US 1985-791198	19851025			
	WO 1986-EP598	19861021			
	US 1986-945428	19861222			
OS	MARPAT 111:173977				
GI					



AB The title compds. [I; R1-R3 = C1-6 alkyl not contg. an asym. C-atom, C3-7 cycloalkyl, (un)substituted Ph; R3 may addnl. = CR20:CR21R22; R20 = H, C1-3 alkyl; R21, R22 = H, C1-3 alkyl, Ph; X = S, O; Y = (E)-CH:CH, CH2CH2;  
 Z = CH(OH)CH2CH(OH)CH2CO2R14 or the hydroxypyranonyl group formed by lactonization thereof; R14 = H, a physiol. acceptable ester group or cation] were prepd. 4-FC6H4CH(OH)CHPhSH (prepn. given) was stirred 4 h with Me2CHCH:C(CO2Et)P(O)(OEt)2 (prepn. given) in THF to give, after Swern oxidn. of the product, 4-FC6H4COCHPhSCH(CHMe2)CH(CO2Et)P(O)(OEt)2 which was stirred 1 h with (Me2CH)2NLi in THF to give, after dicyanobenzoquinone oxidn. of the product, thiophenecarboxylate II (R = CO2Et, R3 = Ph). The latter was converted in 2 steps to II (R = CHO, R3 = Ph) which was added to a soln. of cis-BrCH:CHOEt in THF which was stirred 2 h at -78.degree.

with Me<sub>3</sub>CLi to give, after 10 min addnl. stirring, II (R = CH:CHCHO, R<sub>3</sub> = Ph) which was stirred 1 h at -20.degree. with MeCOCH<sub>2</sub>CO<sub>2</sub>Et in THF which had been treated with BuLi to give, after borane redn. of the product, II [R = CH:CHCH(OH)CH<sub>2</sub>CH(OH)CO<sub>2</sub>Et, R<sub>3</sub> = Ph]. II [R = CH:CHCH(OH)CH<sub>2</sub>CH(OH)CO<sub>2</sub>Na, R<sub>3</sub> = CHMe<sub>2</sub>) (III) had EC<sub>50</sub> of 0.076 mg/kg orally for inhibition of cholesterol biosynthesis in rats. Capsules were prepd. each contg. III 0.5, starch 248.5, and Mg stearate 1 mg.

IT 113070-86-3P 113070-96-5P 123094-03-1P


123094-04-2P 123094-05-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and reaction of, in prepn. of anticholesteremics)

RN 113070-86-3 CAPLUS

CN 2-Propenal, 3-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-phenyl-3-furanyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 113070-96-5 CAPLUS

CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-thienyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123094-03-1 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 123094-04-2 CAPLUS

CN 2-Propen-1-ol,

3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-  
, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 123094-05-3 CAPLUS

CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-,  
(E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 123094-23-5P 123094-36-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as anticholesteremic)


RN 123094-23-5 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 123094-36-0 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, monosodium salt (9CI) (CA INDEX NAME)




● Na



L28 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1989:173074 CAPLUS  
 DN 110:173074  
 TI Preparation of substituted furans as inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase  
 IN Fobare, William F.; Strike, Donald P.  
 PA American Home Products Corp., USA  
 SO U.S., 7 pp.  
 CODEN: USXXAM  
 DT **Patent**  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4792614	A	19881220	US 1987-82013	19870805
OS	MARPAT 110:173074				
GI					




AB The title compds. [I; R<sup>1</sup> = CH:CHCH(OH)CH<sub>2</sub>CH(OH)CH<sub>2</sub>CO<sub>2</sub>R (Q), .delta.-lactone moiety Q<sup>1</sup>; R = H, C1-4 alkyl; 1 of R<sup>2</sup>, R<sup>3</sup> = (un)substituted Ph, the other = H, C1-8 alkyl, halo] and their pharmaceutically acceptable salts were prepd. as inhibitors of hydroxymethylglutaryl CoA (HMG-CoA), and thus useful as anticholesteremics. 4-FC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>Cl underwent Grignard reaction with BrMgCH<sub>2</sub>C.tplbond.CH to give 4-FC<sub>6</sub>H<sub>4</sub>C(CH<sub>2</sub>Cl)(OH)CH<sub>2</sub>C.tplbond.CH which was cyclized by stirring in Et<sub>2</sub>N with powd. NaOH to give 4,5-epoxy-4-(4-fluorophenyl)-1-pentyne. The latter was treated with HgSO<sub>4</sub> in aq. H<sub>2</sub>SO<sub>4</sub> to give I (R<sup>1</sup> = H, R<sup>2</sup> = 4-FC<sub>6</sub>H<sub>4</sub>, R<sup>3</sup> = Me) which was successively condensed with Me<sub>2</sub>NCH:CHCHO in the presence of POCl<sub>3</sub>, and with MeCOCH<sub>2</sub>CO<sub>2</sub>Me dianion at -78.degree. in THF, and reduced with NaBH<sub>4</sub>/BMe<sub>3</sub> in MeOH/THF to give (3S, 5S, E)-I (R<sup>1</sup> = Q, R = Me, R<sup>2</sup> = 4-FC<sub>6</sub>H<sub>4</sub>, R<sup>3</sup> = Me) (II). II inhibited HMG-CoA from rat liver microsomes with an IC<sub>50</sub> of 62.0 .mu.M.

IT **119969-28-7P 119969-30-1P 119969-34-5P 119969-39-0P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and condensation of, with acetoacetate dianion)

RN 119969-28-7 CAPLUS  
 CN 2-Propenal, 3-[3-(4-fluorophenyl)-5-methyl-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 119969-30-1 CAPLUS

CN 2-Propenal, 3-(5-methyl-3-phenyl-2-furanyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 119969-34-5 CAPLUS

CN 2-Propenal, 3-[3-(4-fluorophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 119969-39-0 CAPLUS

CN 2-Propenal, 3-[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT **119969-37-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and hydride redn. of)

RN 119969-37-8 CAPLUS

CN 2-Propenoic acid, 3-[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT **119969-38-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and oxidn. of)

RN 119969-38-9 CAPLUS

CN 2-Propen-1-ol, 3-[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1988:630987 CAPLUS

DN 109:230987

TI Preparation of 6-chloro-2-(nitrophenyl)thieno(3,2-b)furan-5-carboxylic acid chloride

IN Kralovicova, Eva; Krutosikova, Alzbeta; Kovac, Jaroslav

PA Czech.

SO Czech., 3 pp.


CODEN: CZXXA9

DT **Patent**

LA Slovak

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 249490	B1	19870312	CS 1985-7054	19851001
AB	Stirring 2.59 g 3-[5-(2-nitrophenyl)-2-furyl]acrylic acid with 2.27 g PhCH <sub>2</sub> N+Et <sub>3</sub> Cl <sup>-</sup> in 6.4 g SOCl <sub>2</sub> at 135.degree., feeding an addnl. 2.2 g SOCl <sub>2</sub> , stirring 2 h, evapg. SOCl <sub>2</sub> , and extg. the product with C <sub>6</sub> H <sub>6</sub> gave 23.4% title compd.				
IT	<b>58110-36-4</b>				
	RL: RCT (Reactant) (cyclization of)				
RN	58110-36-4	CAPLUS			
CN	2-Propenoic acid, 3-[5-(2-nitrophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)				



L28 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1988:112221 CAPLUS  
 DN 108:112221  
 TI Preparation of (heterocyclylalkenyl)mevalonates as hypolipemics and antiatherosclerotic agents  
 IN Wareing, James Richard; Damon, Robert Edson  
 PA Sandoz A.-G., Switz.; Sandoz-Patent-G.m.b.H.; Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.  
 SO Eur. Pat. Appl., 41 pp.  
 CODEN: EPXXDW  
 DT **Patent**  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 221025	A1	19870506	EP 1986-810470	19861021
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8702662	A2	19870507	WO 1986-EP598	19861021
	WO 8702662	A3	19871217		
	W: AU, DK, FI, HU, JP, KR				
	AU 8665994	A1	19870519	AU 1986-65994	19861021
	AU 598775	B2	19900705		
	JP 63501153	T2	19880428	JP 1986-505883	19861021
	HU 48208	A2	19890529	HU 1986-5313	19861021
	IL 80403	A1	19900917	IL 1986-80403	19861023
	CA 1278794	A1	19910108	CA 1986-521333	19861024
	PL 154130	B1	19910731	PL 1986-262032	19861024
	FI 8702299	A	19870525	FI 1987-2299	19870525
	DK 8703218	A	19870624	DK 1987-3218	19870624
PRAI	US 1985-791198		19851025		
	US 1986-816664		19860107		
	WO 1986-EP598		19861021		

GI



AB The title compds. [I, II; R1, R2 = alkyl, cycloalkyl, (un)substituted Ph; R3 = R4, alkenyl; R4 = H, R1; X = (CH2)m, alkenylene; Y = NR4, O, S; Z = CHOCH2CR5OHCH2CO2H; R5 = H, alkyl; m = 0-3] were prepd. as hypolipemics

and antiatherosclerotic agents (no data).  $\text{PhCOCH}_2\text{CH}(\text{CHMe}_2)\text{COCO}_2\text{Et}$  (prepn. given) and 4-FC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> were refluxed 16 h in PhMe contg.  $\text{TiCl}_4$  to give III (R = CO<sub>2</sub>Et) which was converted in 7 steps to (+-)-erythro-III (R = CH:CHCHOHCH<sub>2</sub>CHOHCH<sub>2</sub>CO<sub>2</sub>Et).


IT 113070-86-3P 113070-93-2P 113070-96-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and condensation of, in prepn. of hypolipemic and antiatherosclerotic agents)

RN 113070-86-3 CAPLUS


CN 2-Propenal, 3-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-phenyl-3-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 113070-93-2 CAPLUS


CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]- (9CI) (CA INDEX NAME)



RN 113070-96-5 CAPLUS

CN 2-Propenal, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-thienyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 113070-92-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and oxidn. of, in prepn. of hypolipemic and  
antiatherosclerotic  
agents)

RN 113070-92-1 CAPLUS

CN 2-Propen-1-ol,

3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-furanyl]-  
(9CI) (CA INDEX NAME)




IT 113070-90-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and redn. of, in prepn. of hypolipemic and antiatherosclerotic  
agents)

RN 113070-90-9 CAPLUS

CN 2-Propenoic acid, 3-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-phenyl-3-  
furanyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 113071-38-8P 113071-39-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as hypolipemic and antiatherosclerotic agent)

RN 113071-38-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, ethyl ester, [R\*,S\*-(E)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
Double bond geometry as shown.



RN 113071-39-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-(2-methyl-1-propenyl)-3-thienyl]-3,5-dihydroxy-, monosodium salt, [R\*,S\*-(E)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.




● Na



L28 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1986:168825 CAPLUS  
 DN 104:168825  
 TI Glutamic acid diamide derivatives and their use as antiulcer agents  
 PA Toyama Chemical Co., Ltd. , Japan  
 SO Belg., 77 pp.  
 CODEN: BEXXAL  
 DT **Patent**  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 901229	A1	19850606	BE 1984-214130	19841206
	JP 61001651	A2	19860107	JP 1984-120584	19840612
	JP 04066230	B4	19921022		
	DK 8405636	A	19851213	DK 1984-5636	19841128
	DK 168005	B1	19940117		
	GB 2160197	A1	19851218	GB 1984-30081	19841128
	GB 2160197	B2	19880217		
	CA 1265801	A1	19900213	CA 1984-468866	19841128
	DE 3444046	A1	19851212	DE 1984-3444046	19841203
	DE 3444046	C2	19901129		
	US 4610983	A	19860909	US 1984-677466	19841203
	SE 8406141	A	19851213	SE 1984-6141	19841204
	SE 456161	B	19880912		
	FR 2565587	A1	19851213	FR 1984-18609	19841206
	FR 2565587	B1	19890317		
	NL 8403716	A	19860102	NL 1984-3716	19841206
	NL 193022	B	19980401		
	NL 193022	C	19980804		
	ES 538349	A1	19860316	ES 1984-538349	19841206
	CH 663019	A	19871113	CH 1984-5803	19841206
	FI 8404852	A	19851213	FI 1984-4852	19841207
	FI 81563	B	19900731		
	FI 81563	C	19901112		
	AU 8436398	A1	19851219	AU 1984-36398	19841207
	AU 556097	B2	19861023		
	ES 548220	A1	19861216	ES 1985-548220	19851025
	ES 548221	A1	19861216	ES 1985-548221	19851025
	ES 548222	A1	19861216	ES 1985-548222	19851025
PRAI	JP 1984-120584		19840612		
GI					



AB Amino acid diamides R1R2NCO(CH2)nCH(NHCOZ1R5)CONR3R4 (R1, R2, R3, and R4 = H, alkyl, cycloalkyl, alkenyl, aralkyl; NR1R2 or NR3R4 form a heterocycle;

$n = 1, 2, 3$ ; Z1 = direct bond, alkylene, alkadienylene; R5 = cycloalkyl, acyl, heterocyclic group) were prepd. and they showed anti-ulcer activity. Thus, H-DL-Glu(NHMe)-NPr<sub>2</sub>.HCl was condensed with 3-(2-furyl)acrylic acid by ClCO<sub>2</sub>Et in the presence of Et<sub>3</sub>N to give DL-glutamic acid diamide I.


IT 100679-37-6P 100679-38-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as anti-ulcer agent)

RN 100679-37-6 CAPLUS

CN Pentanediamide, N5,N5-dimethyl-2-[[1-oxo-3-(5-phenyl-2-furanyl)-2-propenyl]amino]-N1,N1-dipropyl-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 100679-38-7 CAPLUS

CN Pentanediamide, 2-[[3-[5-(4-chlorophenyl)-2-furanyl]-1-oxo-2-propenyl]amino]-N5,N5-dimethyl-N1,N1-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L28 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1985:422927 CAPLUS

DN 103:22927

TI N-Acyl acidic amino acid diamides

PA Toyama Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF

DT **Patent**

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59227847	A2	19841221	JP 1983-101711	19830609
	JP 04060983	B4	19920929		

AB One hundred title compds. RR1NCO(CH2)nCH(CONR2R3)NHCOZR4 [I; R, R1, R2, R3

= H, (un)substituted alkyl; RR1N or R2R3N may form a heterocyclic ring; Z = bond, alkylene, alkenylene, alkadienylene; n = 1-3] were prepd. by, e.g., reaction of RR1NCO(CH2)nCH(CONR2R3)NH2 (II) with R4ZCO2H (III) or their CO2H reactive derivs. Anti-ulceric activity data of I were shown

to

be more potent than proglumide. Thus, 3 g DL-II.HCl (R = Me, R1 = H, R2

=


R3 = Pr, n = 2) was added to a mixt. of III (R4 = furyl, Z = CH:CH) 1.5, Et3N 2.7, and ClCO2Et 1.3 g in CH2Cl2 at -25.degree. to -20.degree. to give, after 1 h, 80% DL-I (R = Me, R1 = H, R2 = R3 = Pr, n = 2, R4 = furyl, Z = CH:CH).

IT **96785-17-0P 96785-18-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 96785-17-0 CAPLUS

CN Pentanediamide, N5,N5-dimethyl-2-[[1-oxo-3-(5-phenyl-2-furanyl)-2-propenyl]amino]-N1,N1-dipropyl- (9CI) (CA INDEX NAME)




RN 96785-18-1 CAPLUS

CN Pentanediamide, 2-[[3-[5-(4-chlorophenyl)-2-furanyl]-1-oxo-2-propenyl]amino]-N5,N5-dimethyl-N1,N1-dipropyl- (9CI) (CA INDEX NAME)



L28 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1985:45699 CAPLUS  
 DN 102:45699  
 TI Penem derivatives and precursors  
 IN Osborne, Neal Frederick  
 PA Beecham Group PLC, UK  
 SO Eur. Pat. Appl., 133 pp.  
 CODEN: EPXXDW  
 DT **Patent**  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 120613	A1	19841003	EP 1984-301255	19840227
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	ZA 8401514	A	19850130	ZA 1984-1514	19840229
	ES 530153	A1	19860401	ES 1984-530153	19840229
	AU 8425189	A1	19840906	AU 1984-25189	19840301
	AU 568119	B2	19871217		
	JP 60001182	A2	19850107	JP 1984-41200	19840302
	ES 537350	A1	19850816	ES 1984-537350	19841102
	ES 537351	A1	19851216	ES 1984-537351	19841102
PRAI	GB 1983-5704		19830302		
	GB 1983-30516		19831116		
GI					



AB Penems I [R = (un)substituted furyl, thienyl, pyrrolyl; R<sub>1</sub> = H, org.]  
 were


prepd. Thus 1-tert-butyldimethylsilyl-4-tritylthio-2-azetidinone was treated with furfural to give II (R<sub>2</sub> = H, R<sub>3</sub> = SiMe<sub>2</sub>CMe<sub>3</sub>) which was acetylated, desilylated, and treated with HCOC<sub>2</sub>H<sub>4</sub>NO<sub>2</sub>-4 to give II [R<sub>2</sub> = Ac, R<sub>3</sub> = CH(OH)CO<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>-4]. Chlorination of the latter compd. and treatment with PPh<sub>3</sub> gave II [R<sub>2</sub> = Ac, R<sub>3</sub> = C(:PPh<sub>3</sub>)CO<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>-4] which was converted to the Ag thiolate and cyclized to give III. Elimination of HOAc from III, with 1,8-diazabicyclo[5.4.0]undec-7-ene and hydrogenolysis gave (Z)-I Na salt (R = 2-furyl, R<sub>1</sub> = H) which had a min. inhibitory concn. against Staphylococcus aureus Russell of 16.0 .mu.g/mL and was synergistic with amoxycillin.

IT **93856-01-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. and ring closure of)  
 RN 93856-01-0 CAPLUS  
 CN Silver, [(4-nitrophenyl)methyl 3-[(acetyloxy)[5-(3-methoxy-3-oxo-1-propenyl)-2-furanyl]methyl]-2-mercapto-4-oxo-.alpha.-(triphenylphosphoranylidene)-1-azetidineacetato]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L28 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1984:571101 CAPLUS  
 DN 101:171101  
 TI 4-Oxo-1,4-dihydronicotinic acid derivatives and their salts and their  
 antibacterial use  
 IN Narita, Hirokazu; Konishi, Yoshinori; Nitta, Jun; Misumi, Shunjiro;  
 Nagaki, Hideyoshi; Kitayama, Isao; Nagai, Yoriko; Watanabe, Yasuo;  
 Matsubara, Nobuyuki; et al.  
 PA Toyama Chemical Co., Ltd. , Japan  
 SO Ger. Offen., 171 pp.  
 CODEN: GWXXBX  
 DT **Patent**  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 3338846	A1	19840503	DE 1983-3338846	19831026
	DE 3338846	C2	19900913		
	JP 59080665	A2	19840510	JP 1982-188930	19821029
	JP 02061947	B4	19901221		
	JP 60089472	A2	19850520	JP 1983-197624	19831024
	JP 06006575	B4	19940126		
	DK 8304930	A	19840430	DK 1983-4930	19831027
	DK 160421	B	19910311		
	DK 160421	C	19910909		
	GB 2130580	A1	19840606	GB 1983-28784	19831027
	GB 2130580	B2	19860129		
	US 4698352	A	19871006	US 1983-546165	19831027
	BE 898123	A1	19840430	BE 1983-211799	19831028
	SE 8305950	A	19840430	SE 1983-5950	19831028
	SE 455092	B	19880620		
	SE 455092	C	19880929		
	FR 2535320	A1	19840504	FR 1983-17355	19831028
	FR 2535320	B1	19870220		
	ES 526903	A1	19851201	ES 1983-526903	19831028
	CH 661505	A	19870731	CH 1983-5853	19831028
	CA 1326023	A1	19940111	CA 1983-440006	19831028
	JP 06234742	A2	19940823	JP 1993-176266	19930623
	JP 07002715	B4	19950118		
PRAI	JP 1982-188930		19821029		
	JP 1983-197624		19831024		
GI					



AB The title compds. I [R = H, a protective group; R1 = substituted aryl, (un)substituted heterocyclyl; R2 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, acyl, aryl, heterocyclyl] (>280 compds.) were prepd. Thus, 4-ClC6H4CH:CHCOCH2CO2Me was condensed with 4-FC6H4NH2 and Me2NCH(OMe)2 to give

4-ClC6H4CH:CHCOC(CO2Me):CHNHC6H4F-

4, which was cyclized by heating at 140.degree. in DMF to give tetrahydronicotinate II. II was dehydrogenated by heating in C6H6 with 2,3-dichloro-5,6-dicyano-p-benzoquinone and sapond. to give I (R = H, R1

=

4-FC6H4, R2 = 4-ClC6H4) (III). I are effective against a variety of bacterial strains. III had a min. inhibitory concn. against Staphylococcus aureus FDA209P of 6.23 mcg/mL.


IT 92362-83-9 92364-24-4

RL: RCT (Reactant)

(aminomethylenation of)

RN 92362-83-9 CAPLUS


CN 4-Pentenoic acid, 3-oxo-5-(5-phenyl-2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 92364-24-4 CAPLUS

CN 4-Pentenoic acid, 5-[3-(4-nitrophenyl)-2-thienyl]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)





IT 92362-74-8P 92363-52-5P 92363-53-6P


92364-16-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and cyclization of)

RN 92362-74-8 CAPLUS


CN 4-Pentenoic acid,

2-[[ (4-hydroxyphenyl)amino]methylene]-3-oxo-5-(5-phenyl-2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 92363-52-5 CAPLUS

CN 4-Pentenoic acid, 3-oxo-5-(5-phenyl-2-thienyl)-2-[(4-pyridinylamino)methylene]-, methyl ester (9CI) (CA INDEX NAME)




RN 92363-53-6 CAPLUS

CN 4-Pentenoic acid, 2-[[ (4-hydroxyphenyl)amino]methylene]-3-oxo-5-[5-(2-pyridinyl)-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 92364-16-4 CAPLUS

CN 4-Pentenoic acid, 2-[[ (4-fluorophenyl)amino]methylene]-5-[3-(4-nitrophenyl)-2-thienyl]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)




L28 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2001 ACS  
AN 1977:527659 CAPLUS  
DN 87:127659  
TI Treating inflammation with trans-5-(4-chlorophenyl)-2-furanacrylic acid  
IN Goldenberg, Marvin M.  
PA Morton-Norwich Products, Inc., USA  
SO U.S., 2 pp.  
CODEN: USXXAM

DT **Patent**  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 4036981	A	19770719	US 1976-704122	19760712
GI					



AB A method of healing inflammation involves oral administration of trans-5-(4-chlorophenyl)-2-furanacrylic acid (I) [62806-34-2]. Thus, oral administration of 300 mg I/kg to rats caused 77.5% and 74.6% inhibition of carrageenan-induced edema at 4 and 6 h, resp., after administration. No untoward pharmacol. effects were obsd. at this dose.

IT **62806-34-2**


RL: BAC (Biological activity or effector, except adverse); BIOL  
(Biological study)  
(inflammation-inhibitory activity of)

RN 62806-34-2 CAPLUS

CN 2-Propenoic acid, 3-[5-(4-chlorophenyl)-2-furanyl]-, (E)- (9CI) (CA


INDEX  
NAME)

Double bond geometry as shown.



L28 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2001 ACS  
 AN 1976:135452 CAPLUS  
 DN 84:135452  
 TI Furan derivatives  
 IN Yoshina, Shigetaka  
 PA Japan  
 SO Japan. Kokai, 5 pp.  
 CODEN: JKXXAF  
 DT **Patent**  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 50121261	A2	19750923	JP 1974-28299	19740312
GI					



AB 3,4-Diphenylfurans I (R1 = H, alkyl, alkoxy; m, n = 0, 1; R2 = alkyl, aryl, CO2H, CO2Et, furyl) were treated with aminoguanidine to give II.

II are antitubercular, fungicidal and protozoacidal agents (no data). Thus, 1 g 3,4-diphenyl-2-acetofuran, 0.5 g aminoguanidine carbonate, 1 ml concd.


HCl and EtOH was refluxed 1 hr to give 0.3 g II (R1 = H, m = n = 0, R2 = Me). Similarly prepd. were II (R1, m, n, R2 given): H, 1, 1, 2-furyl; H, 1, 0, CO2H; 4-MeO, 0, 0, Me; 4-Me, 0, 0, Me.

IT 57386-07-9P 57386-08-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction with aminoguanidine)


RN 57386-07-9 CAPLUS

CN 3-Buten-2-one, 4-(3,4-diphenyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 57386-08-0 CAPLUS

CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo- (9CI) (CA INDEX NAME)




IT **58849-08-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 58849-08-4 CAPLUS

CN 3-Butenoic acid, 4-[3,4-bis(4-methoxyphenyl)-2-furanyl]-2-oxo- (9CI) (CA  
INDEX NAME)




IT **57386-12-6 57386-13-7 57386-16-0**

**57386-19-3 57386-23-9**

RL: RCT (Reactant)  
(reaction of, with aminoguanidine)


RN 57386-12-6 CAPLUS

CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-phenyl- (9CI) (CA  
INDEX NAME)




RN 57386-13-7 CAPLUS

CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(4-methoxyphenyl)-  
(9CI)  
(CA INDEX NAME)




RN 57386-16-0 CAPLUS

CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 57386-19-3 CAPLUS

CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 57386-23-9 CAPLUS

CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L28 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1976:90187 CAPLUS

DN 84:90187

TI Triazine derivatives

IN Yoshina, Shigetaka

PA Japan

SO Japan. Kokai, 3 pp.

CODEN: JKXXAF

DT **Patent**

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50121289	A2	19750923	JP 1974-28298	19740312

GI For diagram(s), see printed CA Issue.


AB Triazines I (R1 = H, OH) and their salts were prepd. by heating aminoguanidines II (R = alkoxy carbonyl, p-ON2C6H4CH:CH) or their salts.

I had antibacterial and protozoacidal activities (no data). Thus, a mixt. of 1 g II.cntdot.HCl (R = p-ON2C6H4CH:CH) (III) and 0.2 g NaHCO3 in DMF was heated 1.5 hr to 130.degree. and 0.5 hr at 130.degree. to give 0.5 g I (R1 = H). I (R1 = OH) was also prepd. 3,4-Diphenyl-2-furfural (10 g), 200 ml acetone and H2O was treated with 33% aq. NaOH 4 hr at room temp. to give 4.5 g 3,4-diphenyl-2-furfurylideneacetone, which (1 g) in 50% aq. EtOH was treated with 0.4 g 4-O2NC6H4CHO and 1 ml 10% NaOH 4 hr at room temp. to give 0.9 g 1-(3,4-diphenyl-2-furyl)-5-(4-nitrophenyl)-1,4-pentadien-3-one, which (1.7 g) was refluxed with 0.5 g aminoguanidine bicarbonate in EtOH and 1 ml HCl to give 1.7 g III.

IT **57386-08-0P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and esterification of)

RN 57386-08-0 CAPLUS

CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo- (9CI) (CA INDEX NAME)




IT **57386-19-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction with aminoguanidine bicarbonate)

RN 57386-19-3 CAPLUS

CN 1,4-Pentadien-3-one, 1-(3,4-diphenyl-2-furanyl)-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)






IT **57386-23-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and reaction with aminoguanidine carbonate)

RN 57386-23-9 CAPLUS

CN 3-Butenoic acid, 4-(3,4-diphenyl-2-furanyl)-2-oxo-, ethyl ester (9CI)  
(CA

INDEX NAME)




IT **57386-07-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and reaction with benzaldehyde)

RN 57386-07-9 CAPLUS

CN 3-Buten-2-one, 4-(3,4-diphenyl-2-furanyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2001 ACS

AN 1974:120741 CAPLUS

DN 80:120741

TI Diphenylfurans

IN Yoshina, Shigetaka

SO Japan. Kokai, 7 pp.

CODEN: JKXXAF

DT **Patent**

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48091055	A2	19731127	JP 1972-24859	19720310
GI	For diagram(s), see printed CA Issue.				
AB	The bactericidal and fungicidal title compds. (I R1, R2 = H, alkyl, alkoxy; R3 = H or NO2; n = 0 or 1; R4 = H, substituted amino, quinolyl, substituted quinolyl, aryl, C(:NH)NH, etc.) were prepd. by treating aldehydes (II) with amines. E.g., 1 g II (R1 = R2 = p-OMe, R3 = H, n = 0) in EtOH was refluxed 30 min with 0.36 g NH2CONHNH2.HCl to give 1 g I (R4 = NHCONH2, the other symbols the same as before). Similarly prepd. were the following I (R1, R2, R3, R4, and n given): H, H, H, NHCONH2, 0; H, H, H, NHCONH2, 1; p-OMe, p-OMe, H, OH, 0; H, H, NO2, NHC(:NH)NH, 0; H, H, NO2, 3-quinolyl, 0.				
IT	<b>52101-43-6</b>				
	RL: RCT (Reactant) (reaction of, with semicarbazide)				
RN	52101-43-6 CAPLUS				
CN	2-Propenal, 3-(3,4-diphenyl-2-furanyl)- (9CI) (CA INDEX NAME)				

